Equity Research Chemicals & Allied Products

Should You Buy Innospec Inc. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Innospec Inc. (IOSP) is rated as a strong fundamental performer with a QOC score of 8.4/10. Trading at $83.95, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.

The short answer: 4 of 13 CirclFi valuation models project upside for Innospec Inc. (IOSP) at $83.95 — the model consensus leans bearish, with a Quality Score of 8.4/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 9 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 8.4/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: 6/100 — Minimal — healthy fundamentals
  • Fair Value Range: $25.94 – $171.77 (562% spread)

Bullish Models

4 / 13

Bearish Models

9 / 13

Quality Score

8.4 /10

Excellent — top-tier fundamentals

Value Trap Risk

6 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

13 /13
Active Models

Avg. confidence: 47%

Investment Thesis

The Bull Case

Target: $171.77 (+104.6% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Innospec Inc.'s rating of 8.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably.
  • According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $171.77 (+104.6%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
  • Industry tailwind: aftermarket and services growth could provide meaningful support for Innospec Inc.'s revenue and margin trajectory in the Chemicals & Allied Products space.

The Bear Case

Target: $25.94 (-69.1%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $25.94 (-69.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +173.7% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: supply chain bottlenecks represents a meaningful risk for Innospec Inc. and its Chemicals & Allied Products peers.

Peer Benchmarking

BCPC Balchem Corporation
8.8
SOLS Solstice Advanced Ma
8.7
FMC FMC Corporation
6.6
ECVT Ecovyst Inc.
6.4
HUN Huntsman Corporation
6.4

Valuation Divergence

Spread

562%

Fair Value Range

$25.94 – $171.77

A 562% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

First Chicago

$171.77 (+104.6%)

Most Bearish

Dynamic NAV

$25.94 (-69.1%)

Key Risk Factors

Model Disagreement

562% spread signals high variance in projections.

Bearish Consensus

9/13 models suggest overvaluation.

Macro/Sector Risk

Chemicals & Allied Products headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View IOSP Data Page →

The Bottom Line

Caution dominates our read on Innospec Inc. at $83.95. 8 of 13 models see limited upside or outright downside, with the composite fair value at $78.39 (-6.6%). Quality at 8.4/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. Innospec Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy IOSP stock right now?

Based on CirclFi's multi-model analysis, 4 of 13 models see upside for IOSP at $83.95. The models are divided, which means the investment case depends heavily on your assumptions about Innospec Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Innospec Inc.?

Key risks include: wide model disagreement (562% spread), signaling high uncertainty; general market and sector-specific risks affecting Chemicals & Allied Products companies. Always diversify and consult a financial advisor.

How does IOSP compare to its competitors?

Among Chemicals & Allied Products peers, IOSP holds a Quality Score of 8.4/10. Comparable companies include BCPC (QOC 8.8), SOLS (QOC 8.7), FMC (QOC 6.6). The relative ranking helps investors identify whether IOSP offers better fundamental quality than alternatives in the same sector.

Is IOSP a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. IOSP's Quality Score of 8.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy IOSP at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $25.94 to $171.77. At $83.95, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for IOSP.

View IOSP Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →